Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
9.47
+0.47 (5.22%)
Aug 1, 2025, 5:29 PM CET
5.22%
Market Cap468.76M
Revenue (ttm)-1.44M
Net Income (ttm)-123.27M
Shares Out52.08M
EPS (ttm)-2.45
PE Ration/a
Forward PE55.94
Dividendn/a
Ex-Dividend Daten/a
Volume65,694
Average Volume107,830
Open9.01
Previous Close9.00
Day's Range8.91 - 10.00
52-Week Range4.46 - 11.00
Beta0.66
RSI59.72
Earnings DateAug 21, 2025

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 28
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.